{"id":499530,"date":"2020-07-29T14:56:02","date_gmt":"2020-07-29T14:56:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499530"},"modified":"2020-07-29T14:56:02","modified_gmt":"2020-07-29T14:56:02","slug":"attentiondeficithyperactivity-disorder-adhd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/attentiondeficithyperactivity-disorder-adhd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_499530.html","title":{"rendered":"Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Attention-Deficit\/Hyperactivity Disorder (ADHD), historical and forecasted epidemiology as well as the Attention-Deficit\/Hyperactivity Disorder (ADHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Attention-deficit\/hyperactivity disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and\/or hyperactivity-impulsivity that interferes with functioning or development. ADHD is a group of behaviors and is also called as attention deficit disorder (ADD). ADHD is a behavioral disorder that includes symptoms such as inattentiveness, hyperactivity, and impulsiveness.<\/p>\n<p style=\"text-align: justify;\">Symptoms of ADHD tend to be noticed at an early age and may become more noticeable when a child&#8217;s circumstances change, such as when they start school. Most cases are diagnosed when children are 6 to 12 years old. The symptoms of ADHD usually improve with age, but many adults who were diagnosed with the condition at a young age continue to experience problems. People with ADHD may also have additional problems, such as sleep and anxiety disorders.<\/p>\n<p style=\"text-align: justify;\"><strong>According to a study conducted by Guifeng et al. titled &ldquo;Twenty-Year Trends in Diagnosed AttentionDeficit\/Hyperactivity Disorder among US Children and Adolescents, 1997&ndash;2016,&rdquo; published in 2018, estimated the prevalence of diagnosed attention-deficit\/hyperactivity disorder increased significantly between 1997 and 2016. It has also been observed that the prevalence in children varied between 7.7% and 13.5%.<\/strong><\/p>\n<p style=\"text-align: justify;\"><span><span>&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get FREE sample copy at:&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market\">https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market<\/a><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"attention-deficit-hyperactivity-disorder-adhd-market\" src=\"https:\/\/www.abnewswire.com\/uploads\/063458dfa9d04ea9195196807b91c482.jpg\" alt=\"attention-deficit-hyperactivity-disorder-adhd-market\" \/><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Attention-Deficit\/Hyperactivity Disorder (ADHD) market<\/strong> report also covers emerging drugs, current treatment practices, Attention-Deficit\/Hyperactivity Disorder (ADHD) market share of the individual therapies, current and forecasted Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Attention-Deficit\/Hyperactivity Disorder (ADHD) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Key Facts<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;As per DelveInsight&rsquo;s assessment based on the recent studies and registries, estimated that the European 5 countries and US accounts for the 61% and 28% of the total prevalent cases out of all the ADHD cases in seven major markets in 2017.<\/p>\n<p style=\"text-align: justify;\">Among the European countries, France had the highest diagnosed prevalent population of ADHD with 2,387,148 cases, followed by Italy in 2017.<\/p>\n<p style=\"text-align: justify;\">As per the DelveInsight&rsquo;s Analysis, it is observed that severe Attention Deficit Hyperactivity Disorder (ADHD) cases are found more in males than in females.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Key Benefits of Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Report<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\"><strong>Attention-Deficit\/Hyperactivity Disorder (ADHD) market report<\/strong> provides an in-depth analysis of <\/span><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Size, Share, Trend, Epidemiology and Market Forecast<\/span><span data-mce-mark=\"1\"> till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The Attention-Deficit\/Hyperactivity Disorder (ADHD) market report will help in developing business strategies by understanding the <\/span><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) Market trends &amp; developments<\/span><span data-mce-mark=\"1\">, key players and future market competition that will shape and drive the Attention-Deficit\/Hyperactivity Disorder (ADHD) market in the upcoming years.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The Attention-Deficit\/Hyperactivity Disorder (ADHD) market report covers <\/span><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) current treatment practices, emerging drugs, market share<\/span><span data-mce-mark=\"1\"> of the individual therapies in 7 MM.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The report provides a detailed assessment of the <\/span><strong><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) market<\/span><\/strong><span data-mce-mark=\"1\"> in terms of market drivers &amp; barriers, Unmet Needs, market opportunities, patient population,&nbsp; comparative analysis of pipeline products with detailed clinical profiles, and other factors.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market\" target=\"_blank\"><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) Market<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The total market size of ADHD is calculated by including both the market size for children and adults. The Attention-deficit\/hyperactivity disorder (ADHD) market is expected to show positive growth in the coming years. In 2017, the United States accounts for the largest market size of Attention Deficit Hyperactivity Disorder, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key factors such as Robust Pipeline Activity, Increased public awareness are expected to drive the Attention-deficit\/hyperactivity disorder (ADHD) market forward in the coming years.<\/strong><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The <\/span><strong><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) market outlook<\/span><\/strong><span data-mce-mark=\"1\"> section of the report helps to build the detailed comprehension of the historic, current and forecasted Attention-Deficit\/Hyperactivity Disorder (ADHD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report gives a thorough detail of <\/span><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) market trend<\/span><span data-mce-mark=\"1\"> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market\" target=\"_blank\"><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) Epidemiology<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Attention Deficit Hyperactivity Disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and\/or hyperactivity-impulsivity that interferes with functioning or development. Inattention and hyperactivity\/impulsivity are the key behaviors of ADHD. Some people with ADHD only have problems with one of the behaviors, while others have both inattention and hyperactivity-impulsivity. Most children have the combined type of ADHD.<\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">&nbsp;<\/span><span data-mce-mark=\"1\">The <strong>Attention-Deficit\/Hyperactivity Disorder (ADHD) epidemiology<\/strong> section covers insights about <\/span><span data-mce-mark=\"1\">historical and current Attention-Deficit\/Hyperactivity Disorder (ADHD) patient pool and forecasted trends<\/span><span data-mce-mark=\"1\"> for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) Drugs Uptake and Key Market Players<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The <\/span><strong><span data-mce-mark=\"1\">Attention-Deficit\/Hyperactivity Disorder (ADHD) Drugs Uptake<\/span><\/strong><span data-mce-mark=\"1\"> section focuses on the rate of uptake of the potential drugs recently launched in the Attention-Deficit\/Hyperactivity Disorder (ADHD) market or expected to get launched in the market during the study period. The analysis covers Attention-Deficit\/Hyperactivity Disorder (ADHD) market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp; &nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/span><\/p>\n<p style=\"text-align: justify;\">Some of the leading Companies worldwide, are coming up with novel therapeutic approaches that can entirely change the treatment landscape of Attention Deficit Hyperactivity Disorder (ADHD) in the coming years.<\/p>\n<p style=\"text-align: justify;\"><strong>Key pharma players in the Attention-deficit\/hyperactivity disorder (ADHD) market.<\/strong><br \/>KemPharm<br \/>Supernus Pharmaceuticals<br \/>Sumitomo Dainippon Pharma<br \/>Otsuka Pharmaceuticals<br \/>AEVI Genomic Medicine<br \/>Amarantus Bioscience<br \/>NLS Pharma<br \/>RespireRx Pharmaceuticals <br \/>And many more<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs Covered<\/strong><br \/>Dasotraline<br \/>SPN-812<br \/>centanafadine<br \/>KP415<br \/>KP484<br \/>AEVI-001<br \/>Eltoprazine<br \/>NLS-1 mazindol CR <br \/>CX717<br \/>And many more<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. Executive Summary&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. Attention-Deficit\/Hyperactivity Disorder (ADHD) Competitive Intelligence Analysis<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Overview at a Glance<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">5. Attention-Deficit\/Hyperactivity Disorder (ADHD) Disease Background and Overview<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">6. Attention-Deficit\/Hyperactivity Disorder (ADHD) Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">7. Attention-Deficit\/Hyperactivity Disorder (ADHD) Epidemiology and Patient Population<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">8. Attention-Deficit\/Hyperactivity Disorder (ADHD) Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">9. Attention-Deficit\/Hyperactivity Disorder (ADHD) Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">10. Key Endpoints of Attention-Deficit\/Hyperactivity Disorder (ADHD) Treatment<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">11. Attention-Deficit\/Hyperactivity Disorder (ADHD) Marketed Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">12. Attention-Deficit\/Hyperactivity Disorder (ADHD) Emerging Therapies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">13. Attention-Deficit\/Hyperactivity Disorder (ADHD) Seven Major Market Analysis<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">14. Attribute Analysis<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">15. Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Outlook (7 major markets)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">16. Attention-Deficit\/Hyperactivity Disorder (ADHD) Access and Reimbursement Overview<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">17. KOL Views on the Attention-Deficit\/Hyperactivity Disorder (ADHD) Market.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">18. Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">19. Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Barriers<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">21. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">22. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Related Reports<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-epidemiology-forecast\">Attention-deficit\/hyperactivity disorder (ADHD) Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s Attention-deficit\/hyperactivity disorder (ADHD) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Attention-deficit\/hyperactivity disorder (ADHD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-pipeline-insight\"><span data-mce-mark=\"1\">Attention-deficit\/hyperactivity disorder (ADHD) Pipeline Insights, 2020<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Attention-deficit\/hyperactivity disorder (ADHD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Attention-deficit\/hyperactivity disorder (ADHD) market.<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span>About&nbsp;<\/span><span>DelveInsight<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Anuj Rawat<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=attentiondeficithyperactivity-disorder-adhd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=attentiondeficithyperactivity-disorder-adhd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research DelveInsight&#8217;s &#8220;Attention-Deficit\/Hyperactivity Disorder (ADHD) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Attention-Deficit\/Hyperactivity Disorder (ADHD), historical and forecasted epidemiology as well as the Attention-Deficit\/Hyperactivity Disorder (ADHD) market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/attentiondeficithyperactivity-disorder-adhd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_499530.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-499530","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=499530"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499530\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=499530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=499530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=499530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}